MKI67 and glioblastoma: Despite how the KDM5C levels do not significantly associate either with clinicopathological characteristics (Table S1) or survival (Figure S1B) in the two GBM subgroups, significant changes in Ki67 and p53 protein expressions were observed in KDM5CLow patients with (Epilepsy+) compared to those without epilepsy (Epilepsy−) and in KDM5CLow patients with (IDHmut) or without (IDHWT) IDH1/2 mutation (Figure 1C), respectively.